Patients with cryptogenic stroke treated with routine transcatheter patent foramen ovale closure have increased 4-year stroke risk.

"US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024" was originally created and ...

Axxcess Wealth Management LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 14.2% during ...

It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under ...

Edwards categorizes its therapies and technologies into four categories: Transcatheter Aortic Valve Replacement ("TAVR"), Transcatheter Mitral and Tricuspid Therapies ("TMTT"), Surgical Structural ...

NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...

reported here at Transcatheter Cardiovascular Therapeutics (TCT) 2024. For the primary composite outcome — cardiovascular death, MI, stroke, and ischemia-driven revascularization — the event curves in ...